NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

SAR3419 in Acute Lymphoblastic Leukemia

TerminatedPhase 2

Sponsor: Sanofi

Conditions: Acute Lymphocytic Leukaemia

Interventions: SAR3419

Countries: United States, France

Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: * Response duration * Progression Free Survival * Minimal residual disease * Safety * Pharmacokinetics

Eligibility overview

Sex: ALL

Age: 16 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion criteria:

* Previously treated Acute Lymphoblastic Leukemia of B cell origin (including Burkitt's lymphoma) in relapse or primary refractory. Patients in first relapse will be eligible regardless of the first remission duration.
* No more than 3 prior salvage therapies.
* Philadelphia positive patients failing treatment with imatinib mesylate are accepted.
* CD19 positive patients.

Exclusion criteria:

None

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (11)

Denver, Colorado, United States
Nashville, Tennessee, United States
Houston, Texas, United States
San Antonio, Texas, United States
Milwaukee, Wisconsin, United States
Amiens, France
Paris, France
Pessac, France
Pierre-Bénite, France
Rennes, France
Strasbourg, France